

6.1 bis WHO Coordination of Pandemic Preparedness and Response

WHO will coordinate influenza pandemic preparedness and response in accordance with applicable IHR provisions, paying particular attention to policies and practices to promote the fair and transparent allocation of scarce medical resources (including, but not limited to, vaccines, antivirals and diagnostic materials) during pandemics based on public health risk and needs, including the epidemiology of the pandemic. During inter-pandemic periods, WHO will work with Member States and relevant stakeholders to prepare for the aforementioned role.

6.14 Sustainable and innovative financing mechanisms

6.14.1 unchanged

6.14.2 unchanged

6.14.3 new:

Influenza vaccine, diagnostic and pharmaceutical manufacturers, using the WHO Network system, shall pay an annual partnership contribution to WHO for improving global pandemic influenza preparedness and response. The sum of all annual contributions shall be 50% of the running cost of the [WHO Network]. Such contribution shall commence in 2012. The distribution between companies shall be based on the principles of sustainability, transparency and relative burden sharing. The Director-General in consultation with the "Advisory Group" and in collaboration with the manufacturers will further define the specific amounts to be contributed by each companies as well as the mechanism for implementation, (see section 6.14.5 below).

13.April 2011

6.14.3.1 Member States and other stakeholders are encouraged to consider making specific contributions to WHO for improving global pandemic influenza preparedness and response.

6.14.4

The contribution acquired under 6.14.3 shall be used for improving pandemic preparedness and response, inter alia for conduct disease burden studies, laboratory and surveillance capacity, access and effective deployment of pandemic vaccines and antiviral medicines as decided by the "Advisory Group" together with the Director General.

6.14.5

The contribution obtained shall be guided by the "Advisory Group", comprising X members drawn from X Member States in each WHO region, ref. 7.1.2 and 7.2.3. The Director General shall determine the use of the contribution's and which proportion of contributions referred to in 6.14.3 should be used for inter-pandemic preparedness measures, and which proportion should be reserved for response activities in the event of a pandemic based on advice from the "Advisory Group". When deemed necessary the "Advisory Group" will interact with manufacturers and other stakeholders.

6.14.6

Member States are urged to continue to support the speedy and successful implementation of the WHO Global Pandemic Influenza Action Plan to Increase Vaccine Supply by 2015 by providing adequate financial support in accordance with Framework section 6.13.1 and 6.13.2.

13.April 2011

6.14.7

Member States are urged to support the availability and rapid expansion of the safe use of adjuvant technology through WHO.

6.14.8

Member States are urged to continue and increase their support to strengthen laboratory and surveillance capacity particularly in developing countries by providing adequate financial and technical support in accordance with Framework section 6.6.

7.5 Monitoring and review of the Framework (substitutes present 7.5)

7.5.1 The Director-General, shall on a biannual basis inform the WHA, through the EB, on the status of, and progress on:

(a) Laboratory and surveillance capacity (see Framework section 6.6)

(b) Global influenza vaccine production capacity (see Framework section 6.13.1 and 6.13.2)

(c) Status of agreements entered into with industry, including information on access to vaccines, antivirals and other pandemic material (6.14.3 and 6.14.4)

(d) Financial report on the use of the partnership contribution (6.14.5)

7.5.2 The Framework and its Annexes will be reviewed in 2016 with a view to proposing revisions reflecting developments as appropriate, to the World Health Assembly in 2017, through the Executive Board.